ERBB2 and breast cancer: In this context, the DETECT III phase III trial researchers in Germany are comparing standard therapy alone with standard therapy plus human epidermal growth factor receptor 2 (HER2)-targeted therapy in patients with initially HER2-negative metastatic BC and HER2-positive CTCs [29].